[1. Barton-Davis E.R., Shoturma D.I., Musaro A., Rosenthal N., Sweeney H.L. (1998). Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function, Proc. Natl. Acad. Sci. USA, 95:15603–15607,10.1073/pnas.95.26.15603]Search in Google Scholar
[2. McPherron A.C., Lawler A.M., Lee S.J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member, Nature, 387, 83–90.10.1038/387083a0]Search in Google Scholar
[3. https://www.scientificamerican.com/article/olympics-genedoping-expert/, accessed on 20th of September, 2018.]Search in Google Scholar
[4. https://www.wada_ama.org/sites/default/files/prohibited_l ist_2018_en.pdf, accessed on 20th of September, 2018.]Search in Google Scholar
[5. https://annualmeeting.asgct.org/about_gene_therapy/diseases.php, accessed on 24th of September, 2018.]Search in Google Scholar
[6. MacLaren, R.E. et al. (2014) Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial, The Lancet, 383(9923), 1129-1137.10.1016/S0140-6736(13)62117-0]Search in Google Scholar
[7. Petrs-Silva H., Linden R. (2014). Advances in gene therapy technologies to treat retinitis pigmentosa, Clinical Opthalmology, 8, 127-136.10.2147/OPTH.S38041]Search in Google Scholar
[8. Nathwani A.C. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, The New England Journal of Medicine, 365(25), 2357-2365.]Search in Google Scholar
[9. Nienhuis A.W. (2013). Development of gene therapy for blood disorders: an update, Blood 122(9), 1556-1564.10.1182/blood-2013-04-453209]Search in Google Scholar
[10. Wells D.J. (2008). Gene doping: the hype and the reality, Br J Pharmacol. Jun, 154(3), 623-631.10.1038/bjp.2008.144]Search in Google Scholar
[11. http://am.e_nformation.ro/login?url=http://www.webofkno wledge.com, accessed on 25th of September, 2018.]Search in Google Scholar
[12. https://www.wada-ama.org/en/gene-doping, accessed on 12th of September, 2018.]Search in Google Scholar
[13. https://www.wada_ama.org/sites/default/files/prohibited_l ist_2018_summary_of_modifications_en.pdf, accessed on 12th of September, 2018.]Search in Google Scholar
[14. Lunde G.I., Ekmark M., Rana Z.A., Buonanno A., Gundersen K. (2007). PPARδ expression is influenced by muscle activity and induces slow muscle properties in adult rat muscles after somatic gene transfer, J Physiol., 582(3),1277–1287.10.1113/jphysiol.2007.133025]Search in Google Scholar
[15. Wang Y.X., Zhang C.L, Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H., Evans R.M. (2004). Regulation of muscle fiber type and running endurance by PPARdelta, PLoS Biol., Oct., 2(10): e294.10.1371/journal.pbio.0020294]Search in Google Scholar
[16. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., Gonzalez F.J., Ham J., Kang H., Peters J.M., Evans R.M.(2006). PPARδ regulates glucose metabolism and insulin sensitivity, Proc. Natl. Acad. Sci., 103, 3444–3449.10.1073/pnas.0511253103]Search in Google Scholar
[17. Brzeziańska E., Domańska D., & Jegier A. (2014). Gene doping in sport–perspectives and risks, Biology of sport, 31(4), 251-259.10.5604/20831862.1120931]Search in Google Scholar
[18. Shyu K.G., Chang H., Wang B.W., Kuan P. (2003). Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia, Am. J. Med., 1, 85–92.10.1016/S0002-9343(02)01392-X]Search in Google Scholar
[19. Lippi G., Guidi G.C. (2004). Gene manipulation and improvement of athletic performances: new strategies in blood doping, Br. J. Sports Med., 38: 641.10.1136/bjsm.2004.013623]Search in Google Scholar
[20. Winder W.W., Hardie D.G. (1999). AMP–activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes, Am. J. Physiol., 277: E1–E10.10.1152/ajpendo.1999.277.1.E1]Search in Google Scholar
[21. Rantzau C., Christopher M., Alford F.P. (2008). Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism, J. Appl. Physiol.,104, 363–370.10.1152/japplphysiol.00500.2007]Search in Google Scholar
[22. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., Mihaylova M.M., Nelson M.C., Zou Y., Juguilon H., Kang H., Shaw R.J., Evans R.M. (2008). AMPK and PPARd agonists are exercise mimetics, Cell, 134, 405–415.10.1016/j.cell.2008.06.051]Search in Google Scholar
[23. Lee S., Barton E.R., Sweeney H.L., Farrar R.P. (2004). Viral expression of insulin–like growth factor–I enhances muscle hypertrophy in resistance–trained rats, J. Appl. Physiol., 96, 1097–1104.10.1152/japplphysiol.00479.2003]Search in Google Scholar
[24. Doessing S., Kjaer M. (2005). Growth hormone and connective tissue in exercise, Scand. J. Med. Sci. Sports,15, 202–210.10.1111/j.1600-0838.2005.00455.x]Search in Google Scholar
[25. Whittemore L.A. et al. (2003). Inhibition of myostatin in adult mice increases skeletal muscle mass and strength, Biochem. Biophys. Res. Commun., 24, 965–971.10.1016/S0006-291X(02)02953-4]Search in Google Scholar
[26. Hakimi P., Yang J., Casadesus G., Massillon D., Tolentino-Silva F., Nye C.K., Cabrera M.E., Hagen D.R., Utter C.B., Baghdy Y., Johnson D.H., Wilson D.L., Kirwan J.P., Kalhan S.C., Hanson R.W. (2007). Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse, J. Biol. Chem., 9, 32844–32855.10.1074/jbc.M706127200]Search in Google Scholar
[27. Beale E., Forest C., Harvey B.J. (2007). PCK1 and PCK2 as candidate diabetes and obesity genes, Cell Biochemistry and Biophysics, 48(2-3), 89-95.10.1007/s12013-007-0025-6]Search in Google Scholar
[28. Wilson S.P., Yeomans D.C., Bender M.A., Lu Y., Goins W.F., Glorioso J.C. (1999). Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus, Proc. Natl. Acad. Sci. USA, 96, 3211–3216.10.1073/pnas.96.6.3211]Search in Google Scholar
[29. Machelska H. et al. (2009). Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain, Mol, Pain. 14(5), 72.10.1186/1744-8069-5-72]Search in Google Scholar
[30. Hao S., Wolfe D., Glorioso J.C., Mata M., Fink D.J. (2009). Effects of transgene-mediated endomorphin-2 in inflammatory pain, Eur. J. Pain, 13, 380–386.10.1016/j.ejpain.2008.05.008]Search in Google Scholar
[31. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., Wilson J.M., Batshaw M.L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80(1-2), 148-58.10.1016/j.ymgme.2003.08.016]Search in Google Scholar
[32. Perry J.K., Starling Emerald B., Mertani H.C., Lobie P.E. (2006). The oncogenic potential of growth hormone, Growth Hormone & IGF Research, 16(5–6), 277-289;10.1016/j.ghir.2006.09.006]Search in Google Scholar
[33. Anderson L., Tamayose J.M., Garcia J.M. (2018). Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects, Molecular and Cellular Endocrinology, 464 (C), 65-74.10.1016/j.mce.2017.06.010]Search in Google Scholar
[34. Bergestrom J. (1993). New aspects of erythropoietin treatment, J. Int. Med., 233,1–18.10.1111/j.1365-2796.1993.tb00998.x]Search in Google Scholar
[35. Gao G., Lebherz C., Weiner D. J., Grant R., Calcedo et al. (2004). Erythropoietin gene therapy leads to autoimmune anemia in macaques, Blood, 103(9), 3300-3302.10.1182/blood-2003-11-3852]Search in Google Scholar
[36. Chenuaud P., Larcher T., Rabinowitz J. E., Provost N., Cherel Y., Casadevall N., Samulski R.J., Moullier P. (2004). Autoimmune anemia in macaques following erythropoietin gene therapy, Blood, 103(9), 3303-3304.10.1182/blood-2003-11-3845]Search in Google Scholar
[37. Horgan J. (2016). Could Olympians Be Tweaking Their Genes?, https://blogs.scientificamerican.com/cross-check/couldolympians-be-tweaking-their-genes/ accessed on 17th of September, 2018.]Search in Google Scholar
[38. Thevis M., Geyer H., Thomas A., Schanzer W. (2011). Trafficking of drug candidates relevant for sports drug testing: Detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet, Drug Testing and Analysis, 3 (5), 331-336.10.1002/dta.283]Search in Google Scholar
[39. Fischetto G., Bermon S. (2013). From Gene Engineering to Gene Modulation and Manipulation: Can We Prevent or Detect Gene Doping in Sports?, Sports Medicine, 43(10), 965-977.10.1007/s40279-013-0075-4]Search in Google Scholar
[40. Friedmann T. (2013). Genetic and cellular approaches to doping and doping detection, WADA Symposium on Gene and Cell Doping, Beijing, retrieved from https://www.wadaama.org/sites/default/files/resources, on12th of September, 2018.]Search in Google Scholar
[41. Baoutina A., Bhat S., Zheng M., Partis L., Dobeson M., Alexander I.E., Emslie K.R. (2016). Synthetic certified DNA reference material for analysis of human erythropoietin transgene and transcript in gene doping and gene therapy, Gene therapy 23(10), 708-717.10.1038/gt.2016.47]Search in Google Scholar
[42. Mullin E. (2018). 2017 Was the Year of Gene-Therapy Breakthroughs, accessed on 27th of October, 2018 https://www.technologyreview.com/s/609643/2017-wasthe-year-of-gene-therapy-breakthroughs/.]Search in Google Scholar
[43. Hall S. (2018). Olympic gene doping: How WADA is managing new performance-enhancing technologies, accessed from https://geneticliteracyproject.org/2018/02/13/ on 10th of October, 2018.]Search in Google Scholar
[44. Rankinen T., Perusse L., Rauramaa R., Rivera M.A., Wolfarth B., Bouchard C. (2004). The human gene map for performance and health-related fitness phenotypes: the 2003 update, Med. Sci. Sports Exerc., 36, 1451 – 1469.10.1249/01.MSS.0000139902.42385.5F]Search in Google Scholar
[45. Wenner M. (2008). How to Be Popular duringthe Olympics: Be H. Lee Sweeney, Gne Dopin Expert, Scientific America, August 15, https://www.scientificamerican.com/article/olympicsgene-doping-expert/ on 12th of September, 2018.]Search in Google Scholar